MedTrace Logo

Evaluate LAE102 in Healthy and Overweight/Obese Subjects

NCT06493084 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-01-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of LAE102 injection in healthy and overweight/obese participants, and also evaluate the preliminary pharmacodynamic effect of multiple dose injections in overweight/obese participants.

Conditions

  • Overweight and Obese Volunteers

Interventions

DRUG

LAE102 intravenous administration

A single dose of LAE102 administered intravenously

DRUG

placebo intravenous administration

A single dose of placebo administered intravenously

DRUG

LAE102 subcutaneous administration

Single dose of LAE102 administered subcutaneously

DRUG

placebo subcutaneous administration

single dose of placebo administered subcutaneously

DRUG

LAE102 multiple subcutaneous administration

Multiple dose of LAE102 administered subcutaneously

DRUG

Placebo multiple subcutaneous administration

Multiple dose of placebo administered subcutaneously

Sponsors & Collaborators

  • Laekna Limited

    lead INDUSTRY

Principal Investigators

  • Xuening Li, Professor · Zhongshan hospital affiliated to Fundan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-25
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06493084 on ClinicalTrials.gov